CCL2 and early-onset autosomal dominant Alzheimer disease: AAV2/1 has been utilized to target neurons for anti-inflammatory effects of dominant-negative chemokine CCL2 mutant, interleukin-10 (IL-10) in mouse models of Alzheimer’s Disease (AD) and brain-derived neurotrophic factor (BDNF) in rat models of Huntington’s Disease [22] [23] [24].